For many traders, how a lot a inventory’s value adjustments over time is essential. This issue can influence your funding portfolio in addition to assist you to evaluate funding outcomes throughout sectors and industries.
FOMO, or the worry of lacking out, additionally performs a job in investing, notably with tech giants and fashionable consumer-facing shares.
What if you happen to’d invested in Precise Sciences (EXAS) ten years in the past? It might not have been simple to carry on to EXAS for all that point, however if you happen to did, how a lot would your funding be value at present?
Precise Sciences’ Enterprise In-Depth
With that in thoughts, let’s check out Precise Sciences’ principal enterprise drivers.
Precise Sciences Company is a molecular diagnostics firm centered on the early detection and prevention of a few of the deadliest types of most cancers. The corporate primarily focuses its analysis and growth (R&D) efforts on three principal areas: colorectal most cancers (CRC) screening, molecular residual illness (MRD) testing and multi-cancer screening (MCED) check growth.
EXAS’ flagship screening product, Cologuard, is a non-invasive, patient-friendly, stool-based DNA (“sDNA”) screening check that makes use of a multitarget method to detect DNA and haemoglobin biomarkers related to colorectal most cancers and pre-cancer. The check is presently indicated for average-risk adults 45 years of age and older.
Moreover, Precise Sciences has an intensive menu of predefined genetic checks for practically all clinically related genes, extra customized panels, and complete germline, entire exome (“PGxome”), and entire genome (“PGnome”) sequencing checks. The precision oncology portfolio delivers actionable genomic insights to tell prognosis and most cancers therapy after a prognosis. Inside this, the corporate incurs revenues by way of Oncotype DX most cancers diagnostic checks and providers.
Precise Sciences additionally operated a COVID-19 Testing Enterprise, which was discontinued within the second quarter of 2023.
Acquisitions additionally stay an essential a part of progress, comparable to Decision Bioscience, Inc. (2023) and OmicEra Diagnostics GmbH (2022). In 2021, the corporate acquired Thrive Earlier Detection Company, Ashion Analytics, LLC, PFS Genomics Inc. and PreventionGenetics, LLC.
At current, Precise Sciences’services and products deal with screening and precision oncology checks.
Screening Exams (76.2% of whole revenues in 2024, up 12.8% from 2023): This primarily consists of laboratory service income from Cologuard and PreventionGenetics checks.
Precision oncology Exams (23.7% of whole revenues in 2024, up 4.1% from 2023): This consists of laboratory service income from international Oncotype DX and remedy choice checks.
Backside Line
Placing collectively a profitable funding portfolio takes a mixture of analysis, persistence, and just a little little bit of danger. For Precise Sciences, if you happen to purchased shares a decade in the past, you are seemingly feeling actually good about your funding at present.
In accordance with our calculations, a $1000 funding made in October 2015 could be value $7,525.12, or a acquire of 652.51%, as of October 23, 2025, and this return excludes dividends however consists of value will increase.
As compared, the S&P 500’s gained 226.40% and the value of gold went up 238.37% over the identical time-frame.
Analysts are anticipating extra upside for EXAS.
Precise Sciences continues to profit from robust adoption of Cologuard amongst suppliers, well being methods and payers. Constructing on this momentum, the brand new Cologuard Plus was launched, which rapidly gained Medicare protection, pricing and inclusion in high quality measure tips. The corporate marked one other vital launch from its pipeline with Oncodetect, advancing the sphere of MRD testing. Precise Sciences’ Precision Oncology workforce secured Medicare reimbursement for Oncodetect, opening entry for most cancers sufferers. Moreover, the corporate goals to enhance buyer expertise by way of its proprietary ExactNexus expertise platform. In the meantime, a extremely leveraged steadiness sheet raises considerations. Persistent escalated bills stay a headwind for Precise Sciences’ profitability. An intense aggressive panorama provides to the dangers.
Over the previous 4 weeks, shares have rallied 18.43%, and there have been 2 greater earnings estimate revisions prior to now two months for fiscal 2025 in comparison with none decrease. The consensus estimate has moved up as effectively.
Radical New Know-how May Hand Buyers Large Beneficial properties
Quantum Computing is the following technological revolution, and it could possibly be much more superior than AI.
Whereas some believed the expertise was years away, it’s already current and transferring quick. Giant hyperscalers, comparable to Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to combine quantum computing into their infrastructure.
Senior Inventory Strategist Kevin Prepare dinner reveals 7 fastidiously chosen shares poised to dominate the quantum computing panorama in his report, Past AI: The Quantum Leap in Computing Energy.
Kevin was among the many early consultants who acknowledged NVIDIA’s huge potential again in 2016. Now, he has keyed in on what could possibly be “the following large factor” in quantum computing supremacy. In the present day, you will have a uncommon probability to place your portfolio on the forefront of this chance.
See Prime Quantum Shares Now >>
Precise Sciences Company (EXAS) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
-1761220847716-1761220847719.png&w=1536&q=95 "Gold companies as buyers weigh US-China talks and Russia sanctions")
